Brian Lian Sells 233,409 Shares of Viking Therapeutics (NASDAQ:VKTX) Stock

by · The Cerbat Gem

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) CEO Brian Lian sold 233,409 shares of Viking Therapeutics stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $32.96, for a total value of $7,693,160.64. Following the completion of the transaction, the chief executive officer owned 2,499,291 shares of the company’s stock, valued at $82,376,631.36. This trade represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Brian Lian also recently made the following trade(s):

  • On Tuesday, October 28th, Brian Lian sold 38,989 shares of Viking Therapeutics stock. The shares were sold at an average price of $35.01, for a total value of $1,365,004.89.

Viking Therapeutics Stock Down 9.3%

Shares of Viking Therapeutics stock traded down $3.28 during midday trading on Monday, hitting $32.14. The company’s stock had a trading volume of 8,255,722 shares, compared to its average volume of 1,999,261. The stock has a 50-day simple moving average of $36.43 and a 200-day simple moving average of $32.36. Viking Therapeutics, Inc. has a 1-year low of $18.92 and a 1-year high of $43.55. The firm has a market capitalization of $3.63 billion, a P/E ratio of -15.16 and a beta of 0.71.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last released its quarterly earnings results on Wednesday, October 22nd. The biotechnology company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.14). During the same quarter in the prior year, the company posted ($0.22) EPS. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. As a group, sell-side analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on VKTX. B. Riley raised Viking Therapeutics to a “strong-buy” rating in a report on Thursday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Wednesday, October 8th. Cantor Fitzgerald set a $105.00 price target on shares of Viking Therapeutics in a research report on Thursday, October 23rd. Canaccord Genuity Group raised their price target on Viking Therapeutics from $106.00 to $107.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Finally, Morgan Stanley increased their target price on Viking Therapeutics from $98.00 to $102.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $87.14.

Get Our Latest Research Report on VKTX

Institutional Investors Weigh In On Viking Therapeutics

Several large investors have recently bought and sold shares of VKTX. Allworth Financial LP raised its position in Viking Therapeutics by 58.4% in the 2nd quarter. Allworth Financial LP now owns 955 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 352 shares during the period. Glass Jacobson Investment Advisors llc acquired a new stake in Viking Therapeutics during the 2nd quarter worth about $28,000. Quarry LP lifted its holdings in Viking Therapeutics by 1,621.4% in the first quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 1,135 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in shares of Viking Therapeutics during the 2nd quarter valued at approximately $29,000. Finally, Golden State Wealth Management LLC purchased a new position in shares of Viking Therapeutics in the third quarter valued at approximately $30,000. Institutional investors own 76.03% of the company’s stock.

Viking Therapeutics Company Profile

(Get Free Report)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.

Featured Articles